Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study  Dr Sabine Vogler, PhD, Agnes Vitry, PhD, Zaheer-Ud-Din Babar, PhD  The Lancet Oncology  Volume 17, Issue 1, Pages 39-47 (January 2016) DOI: 10.1016/S1470-2045(15)00449-0 Copyright © 2016 Elsevier Ltd Terms and Conditions

Figure Boxplot of drug prices (ex-factory price per unit) indexed (price in the lowest priced country=100), as of June 2013, in 16 European countries, Australia, and New Zealand The box displays the interquartile range (IQR); the bottom and top of the box are the 25th and 75th percentiles (the 1st and 3rd quartiles, respectively), and the band near the middle of the box is the median. The dashed lines describe the bottom and top whiskers. The small circles indicate extreme datapoints (commonly referred to as outliers). The blue diamond shows the datapoint for Australia, and the red triangle for New Zealand. The appendix shows boxplots without gemcitabine and without gemcitabine and interferon alfa 2b (for better readability). The Lancet Oncology 2016 17, 39-47DOI: (10.1016/S1470-2045(15)00449-0) Copyright © 2016 Elsevier Ltd Terms and Conditions